Antidepressant-dependent mRNA changes in mouse associated with hippocampal neurogenesis in a mouse model of depression

Pharmacogenetics and Genomics

Volumn 22, Issue 11, 2012, Pages 765-776

  Malki, Karim ^a   Lourdusamy, Anbarasu ^a   Binder, Elke ^b   Payá Cano, Jose ^a   Sluyter, Frans ^a   Craig, Ian ^a   Keers, Robert ^a   McGuffin, Peter ^a   Uher, Rudolf ^a   Schalkwyk, Leonard C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b INSTITUT FRANÇOIS MAGENDIE   (France)

Author keywords

escitalopram; Genome Drugs for Therapeutic Response; nortriptyline; pharmacogenetics; transcriptomics

Indexed keywords

ESCITALOPRAM; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; NORTRIPTYLINE; STRESS ACTIVATED PROTEIN KINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DBA 2 MOUSE; DEPRESSION; GENE EXPRESSION; GENETIC ASSOCIATION; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; MAJOR DEPRESSION; MOUSE; MOUSE STRAIN; NERVOUS SYSTEM DEVELOPMENT; NEUROBIOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; SYSTEMATIC REVIEW;

ANIMALIA;

EID: 84867573849     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328356fa90     Document Type: Article

References (89)

1. Parker G, Hadzi-Pavlovic D, Sengoz A, Boyce P, Mitchell P,Wilhelm K, et al. A brief self-report depression measure assessing mood state and social impairment. J Affect Disord 1994; 30:133-142.
2. Eaton WW, Shao H, Nestadt G, Lee HB, Bienvenu OJ, Zandi P. Populationbased study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry 2008; 65:513-520.
3. Daly EJ, Trivedi MH,Wisniewski SR, Nierenberg AA, Gaynes BN,Warden D, et al. Health-related quality of life in depression: a STAR*D report. Ann Clin Psychiatry 2010; 22:43-55.
4. Ten Doesschate MC, Koeter MW, Bockting CL, Schene AH. Health related quality of life in recurrent depression: a comparison with a general population sample. J Affect Disord 2010; 120:126-132.
5. Nuevo R, Leighton C, Dunn G, Dowrick C, Lehtinen V, Dalgard OS, et al. Impact of severity and type of depression on quality of life in cases identified in the community. Psychol Med 2010; 40:2069-2077.
6. Perroud N, Uher R, Hauser J, Rietschel M, Henigsberg N, Placentino A, et al. History of suicide attempts among patients with depression in the GENDEP project. J Affect Disord 2010; 123:131-137.
7. Hantouche E, Angst J, Azorin JM. Explained factors of suicide attempts in major depression. J Affect Disord 2010; 127:305-308.
8. Cavanagh JT, Carson AJ, Sharpe M, Lawrie SM. Psychological autopsy studies of suicide: a systematic review. Psychol Med 2003; 33: 395-405.
9. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91:999-1005.
10. Ahern DK, Gorkin L, Anderson JL, Tierney C, Hallstrom A, Ewart C, et al. Biobehavioral variables and mortality or cardiac arrest in the Cardiac Arrhythmia Pilot Study (CAPS). Am J Cardiol 1990; 66:59-62.
11. Kaufmann MW, Fitzgibbons JP, Sussman EJ, Reed JF III, Einfalt JM, Rodgers JK, et al. Relation between myocardial infarction, depression, hostility, and death. Am Heart J 1999; 138 (Pt 1):549-554.
12. Martens EJ, Mols F, Burg MM, Denollet J. Type D personality predicts clinical events after myocardial infarction, above and beyond disease severity and depression. J Clin Psychiatry 2010; 71:778-783.
13. Martens EJ, Hoen PW, Mittelhaeuser M, de Jonge P, Denollet J. Symptom dimensions of post-myocardial infarction depression, disease severity and cardiac prognosis. Psychol Med 2010; 40:807-814.
14. Kurdyak PA, Chong A, Gnam WH, Goering P, Alter DA. Depression and selfreported functional status: impact on mortality following acute myocardial infarction. J Eval Clin Pract 2011; 17:444-451.
15. Barefoot JC, Helms MJ, Mark DB, Blumenthal JA, Califf RM, Haney TL, et al. Depression and long-term mortality risk in patients with coronary artery disease. Am J Cardiol 1996; 78:613-617.
16. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998; 4:1241-1243.
17. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 2000; 160:3278-3285.
18. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003; 64:1465-1475.
19. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54:405-418.
20. Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry 2009; 195:102-108.
21. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008; 455:894-902.
22. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002; 34:13-25.
23. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178:234-241.
24. Stewart JW, McGrath PJ, Deliyannides RA, Quitkin FM. Does dual antidepressant therapy as initial treatment hasten and increase remission from depression? J Psychiatr Pract 2009; 15:337-345.
25. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009; 117 (Suppl 1): S26-S43.
26. Ruhe HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006; 67:1836-1855.
27. Marangell LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry 2001; 62 (Suppl 18):12-17.
28. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354:1243-1252.
29. Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry 2000; 61 (Suppl 1):26-32.
30. Trivedi MH. Major depressive disorder: remission of associated symptoms. J Clin Psychiatry 2006; 67 (Suppl 6):27-32.
31. Takahashi Y,Washiyama K, Kobayashi T, Hayashi S. Gene expression in the brain from fluoxetine-injected mouse using DNA microarray. Ann NY Acad Sci 2006; 1074:42-51.
32. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001; 7:541-547.
33. Shelton RC. The molecular neurobiology of depression. Psychiatr Clin North Am 2007; 30:1-11.
34. West DB, Iakougova O, Olsson C, Ross D, Ohmen J, Chatterjee A. Mouse genetics/genomics: an effective approach for drug target discovery and validation. Med Res Rev 2000; 20:216-230.
35. Alberts R, Terpstra P, Hardonk M, Bystrykh LV, de Haan G, Breitling R, et al. A verification protocol for the probe sequences of Affymetrix genome arrays reveals high probe accuracy for studies in mouse, human and rat. BMC Bioinformatics 2007; 8:132.
36. Malki K, Uher R, Paya-Cano J, Binder E, Rietschel M, Zobel A, et al. Convergent animal and human evidence suggests a role of PPM1A gene in response to antidepressants. Biol Psychiatry 2011; 69:360-365.
37. Uher R, Maier W, Hauser J, Marusic A, Schmael C, Mors O, et al. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry 2009; 194:252-259.
38. Rush AJ, Bose A. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depress Anxiety 2005; 21:26-32.
39. Holsboer-Trachsler E, Baumann P, Hock P, Hattenschwiler J, Jost M, Ramseier F, et al. Escitalopram in clinical practice: results of an observational study in patients with depression and anxiety. Psychopharmakotherap 2011; 18:59.
40. Perroud N, Uher R, Marusic A, Rietschel M, Mors O, Henigsberg N, et al. Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trial. BMC Med 2009; 7:60.
41. Fabre LF, Scharf MB, Itil TM. Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression-a clinical-study. J Clin Psychiat 1991; 52:62-67.
42. Binder E, Malki K, Paya-Cano JL, Fernandes C, Aitchison KJ, Mathe AA, et al. Antidepressants and the resilience to early-life stress in inbred mouse strains. Pharmacogenet Genomics 2011; 21:779-789.
43. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4:249-264.
44. Hong F, Breitling R, McEntee CW, Wittner BS, Nemhauser JL, Chory J. RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics 2006; 22:2825-2827.
45. Duman RS, Malberg JE, Eisch AJ, Nestler EJ. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20:9104-9110.
46. Gaysina D, Cohen S, Craddock N, Farmer A, Hoda F, Korszun A, et al. No association with the 5,10-methylenetetrahydrofolate reductase gene and major depressive disorder: results of the depression case control (DeCC) study and a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:699-706.
47. Sibille E, Surget A, Wang Y, Leman S, Ibarguen-Vargas Y, Edgar N, et al. Corticolimbic transcriptome changes are state-dependent and regionspecific in a rodent model of depression and of antidepressant reversal. Neuropsychopharmacology 2009; 34:1363-1380.
48. Licinio J. Sequence Variability in ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1, NTRK2 and BDNF: novel variations and association with depression and antidepressant response. Biol Psychiatry 2010; 67: 193S-194S.
49. Licinio J, Dong C, Wong ML. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry 2009; 14:1105-1118.
50. Wallace DL, Han MH, Graham DL, Green TA, Vialou V, Iniguez SD, et al. CREB regulation of nucleus accumbens excitability mediates social isolation-induced behavioral deficits. Nat Neurosci 2009; 12:200-209.
51. Mochizuki N, Moriyama Y, Takagi N, Takeo S, Tanonaka K. Intravenous injection of neural progenitor cells improves cerebral ischemia-induced learning dysfunction. Biol Pharm Bull 2011; 34:260-265.
52. Blendy JA. The role of CREB in depression and antidepressant treatment. Biol Psychiatry 2006; 59:1144-1150.
53. Andrus BM, Blizinsky K, Vedell PT, Dennis K, Shukla PK, Schaffer DJ, et al. Gene expression patterns in the hippocampus and amygdala of endogenous depression and chronic stress models. Mol Psychiatry 2010; 1:49-61.
54. Surget A, Wang Y, Leman S, Ibarguen-Vargas Y, Edgar N, Griebel G, et al. Corticolimbic transcriptome changes are state-dependent and regionspecific in a rodent model of depression and of antidepressant reversal. Neuropsychopharmacology 2009; 34:1363-1380.
55. Lanctot KL, Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67:446-457.
56. Nishikura K, Yang WD, Wang QD, Kanes SJ, Murray JM, Altered RNA. editing of serotonin 5-HT2C receptor induced by interferon: implications for depression associated with cytokine therapy. Mol Brain Res 2004; 124: 70-78.
57. Guido ME, Rusak B, Robertson HA. Spontaneous circadian and lightinduced expression of junB mRNA in the hamster suprachiasmatic nucleus. Brain Res 1996; 732:215-222.
58. Ehrenreich H, Begemann M, Sargin D, Rossner MJ, Bartels C, Theis F, et al. Episode-specific differential gene expression of peripheral blood mononuclear cells in rapid cycling supports novel treatment approaches. Mol Med 2008; 14:546-552.
59. Wang J, Lou H, Pedersen CJ, Smith AD, Perez RG. 14-3-3zeta contributes to tyrosine hydroxylase activity in MN9D cells: localization of dopamine regulatory proteins to mitochondria. J Biol Chem 2009; 284: 14011-14019.
60. Hahn MK, Blakely RD. The functional impact of SLC6 transporter genetic variation. Annu Rev Pharmacol Toxicol 2007; 47:401-441.
61. Hope BT, Moron JA, Brockington A,Wise RA, Rocha BA. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 2002; 22:389-395.
62. Kim DK, Kim H, Lim SW, Kim S, Kim JW, Chang YH, et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA 2006; 296:1609-1618.
63. Weinberger DR, Pezawas L, Meyer-Lindenberg A, Goldman AL, Verchninski BA, Chen G, et al. Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. Mol Psychiatry 2008; 13: 709-716.
64. Murphy DL, Uhl GR, Holmes A, Ren-Patterson R, Hall FS, Sora I, et al. Experimental gene interaction studies with SERT mutant mice as models for human polygenic and epistatic traits and disorders. Genes Brain Behav 2003; 2:350-364.
65. Ren-Patterson RF, Cochran LW, Holmes A, Sherrill S, Huang SJ, Tolliver T, et al. Loss of brain-derived neurotrophic factor gene allele exacerbates brain monoamine deficiencies and increases stress abnormalities of serotonin transporter knockout mice. J Neurosci Res 2005; 79: 756-771.
66. Potash JB, Verma R, Holmans P, Knowles JA, Grover D, Evgrafov OV, et al. Linkage disequilibrium mapping of a chromosome 15q25-26 major depression linkage region and sequencing of NTRK3. Biol Psychiatry 2008; 63:1185-1189.
67. Duman RS. Depression: a case of neuronal life and death? Biol Psychiatry 2004; 56:140-145.
68. Juhasz G, Dunham JS, McKie S, Thomas E, Downey D, Chase D, et al. The CREB1-BDNF-NTRK2 pathway in depression: multiple gene-cognitionenvironment interactions. Biol Psychiatry 2011; 69:762-771.
69. Schaaf MJ, de Jong J, de Kloet ER, Vreugdenhil E. Downregulation of BDNF mRNA and protein in the rat hippocampus by corticosterone. Brain Res 1998; 813:112-120.
70. Perera TD, Coplan JD, Lisanby SH, Lipira CM, Arif M, Carpio C, et al. Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J Neurosci 2007; 27:4894-4901.
71. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15:7539-7547.
72. Warner-Schmidt JL, Duman RS. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 2006; 16:239-249.
73. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011; 475:91-95.
74. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329:959-964.
75. Cryan JF, Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 2005; 4:775-790.
76. Sequeira A, Mamdani F, Ernst C, Vawter MP, Bunney WE, Lebel V, et al. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One 2009; 4:e6585.
77. Bruchas MR, Schindler AG, Shankar H, Messinger DI, Miyatake M, Land BB, et al. Selective p38alpha MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. Neuron 2011; 71:498-511.
78. Zhong P, Liu W, Gu Z, Yan Z. Serotonin facilitates long-term depression induction in prefrontal cortex via p38 MAPK/Rab5-mediated enhancement of AMPA receptor internalization. J Physioly 2008; 586 (Pt 18): 4465-4479.
79. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59:1116-1127.
80. Carlson PJ, Singh JB, Zarate CA Jr, Drevets WC, Manji HK. Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx 2006; 3:22-41.
81. Carlezon WA Jr., Duman RS, Nestler EJ. The many faces of CREB. Trends Neurosci 2005; 28:436-445.
82. Pandey GN. Cyclic-AMP response element-binding protein and brain-derived neurotrophic factor in mood disorders. Biol Psychiatry 2011; 69:15S.
83. Nair A, Vaidya VA. Cyclic AMP response element binding protein and brainderived neurotrophic factor: molecules that modulate our mood? J Biosciences 2006; 31:423-434.
84. Rantamaki T, Vesa L, Antila H, Di Lieto A, Tammela P, Schmitt A, et al. Antidepressant drugs transactivate TrkB neurotrophin receptors in the adult rodent brain independently of BDNF and monoamine transporter blockade. PLoS One 2011; 6:e20567.
85. Cazorla M, Premont J, Mann A, Girard N, Kellendonk C, Rognan D. Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. J Clin Invest 2011; 121:1846-1857.
86. Castren E, Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 2003; 23:349-357.
87. Nibuya M, Morinobu S, Duman RS. Regulation of Bdnf and Trkb messenger-Rna in rat-brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15:7539-7547.
88. Cecconi D, Mion S, Astner H, Domenici E, Righetti PG, Carboni L. Proteomic analysis of rat cortical neurons after fluoxetine treatment. Brain Res 2007; 1135:41-51.
89. Baik SY, Jung KH, Choi MR, Yang BH, Kim SH, Lee JS, et al. Fluoxetineinduced up-regulation of 14-3-3zeta and tryptophan hydroxylase levels in RBL-2H3 cells. Neurosci Lett 2005; 374:53-57.